menu
    • menu
    [{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NP001","moa":"Macrophage","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ Not Applicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NP001","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ Not Applicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"PrimeStreet Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"NP001","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Neuvivo \/ PrimeStreet Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ PrimeStreet Capital"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chlorite","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neuvivo \/ Not Applicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NP001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neuvivo \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Neuvivo

    Menu

    Neuvivo

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NP001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Breakthrough in ALS Lung Function, Survival Through NP001 Platform

                            Details : NP001 is an HSP90 inhibitor small molecule drug candidate which is currently being evaluated for the treatment of patients with amyotrophic lateral sclerosis.

                            Brand Name : NP001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 16, 2024

                            Lead Product(s) : NP001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorite

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuvivo Seeks FDA Approval for Its Breakthrough ALS Treatment NP001

                            Details : NP001 is an investigational product (sodium chlorite), which is being investigated in the late-stage clinical trial for the treatment of amyotrophic lateral sclerosis.

                            Brand Name : NP001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 07, 2024

                            Lead Product(s) : Chlorite

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NP001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : PrimeStreet Capital

                            Deal Size : $11.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Neuvivo Raises $11M in Venture Financing to Develop Treatment for ALS

                            Details : The financing will be used for the continued development of NP001, a novel regulator of inflammatory macrophages and monocytes, for the treatment of ALS.

                            Brand Name : NP001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 15, 2023

                            Lead Product(s) : NP001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : PrimeStreet Capital

                            Deal Size : $11.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NP001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuvivo's NP001 for Treatment of ALS Slows Disease Progression Through Regulation of Microbial Translocation

                            Details : NP001, is a small molecule which, through a series of biochemical interactions in the body, is converted to a compound that can transform inflammatory macrophages (M1) to the non-inflammatory, wound healing state (M2), with the goal of stopping damage to...

                            Brand Name : NP001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2022

                            Lead Product(s) : NP001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Neuvivo

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NP001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuvivo Begins Manufacturing of NP001 for Treatment of ALS

                            Details : NP001 has been shown to be effective and safe in clinical trials. Published data show a 38% slowing of disease progression as measured by ALSFRS-R score and importantly, a 51% slowing of the decline in lung function compared to placebo.

                            Brand Name : NP001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 11, 2022

                            Lead Product(s) : NP001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth